BioSpace News Archive

Processa Pharmaceuticals, Inc. announces today it will host a conference call and live webcast on November 8, 2022, at 4:30 p.m. EST to discuss its third quarter 2022 results and provide an update on its clinical pipeline.

Surmodics, Inc. today announced that 24-month data from its TRANSCEND clinical trial has been presented at the Vascular InterVentional Advances (VIVA) annual conference in Las Vegas.

BiomX Inc. (NYSE American) today announced that the Company will host a conference call and a live audio webcast on Wednesday, November 9, 2022, at 8:00 a.m. ET, to report third quarter 2022 financial results and provide business updates.

MicroPort Orthopedics is a medical device company specializing in large joint replacements with clinical data/history dating back over 20 years.

Renovion and COPD Foundation Joint Release – Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFBE) (NCT05495243).

CathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the EP lab, today announced the investigation of the Signal Complexity™ algorithm designed to visualize and quantify atrial fibrillation (AF) complexity parameters in patients with persistent AF.

Blu Biotech Inc. entered into a Patent License Agreement with Innovation Partnerships at the University of Michigan (U-M) to develop and commercialize a Micro Gas Chromatography Photoionization Detector (Micro-GC-PID).

NLS Pharmaceutics Ltd. announces that it has received Orphan Drug Designation from the FDA in the United States for Mazindol, the active ingredient in its lead product candidate, Quilience® for the treatment of Idiopathic Hypersomnia.

Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) will be presenting at the Emerging Growth Conference on November 9, 2022 (https://emerginggrowth.com/conference/).

According to Nova one advisor, the global Glioma Treatment market size is expected to hit around USD 7.55 billion by 2030 from valued at USD 4.59 billion in 2021 and growing at a CAGR of 5.14% from 2022 to 2030.